VolitionRx (NYSE:VNRX) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of VolitionRx (NYSE:VNRX) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $2.50 target price on the stock.

VolitionRx Trading Down 2.6 %

NYSE:VNRX opened at $0.73 on Wednesday. The company’s 50 day moving average price is $0.99 and its 200-day moving average price is $0.87. VolitionRx has a 52 week low of $0.55 and a 52 week high of $2.10. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.56. The stock has a market cap of $57.44 million, a price-to-earnings ratio of -1.43 and a beta of 1.38.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, equities research analysts forecast that VolitionRx will post -0.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Vanguard Group Inc. increased its stake in VolitionRx Limited (NYSE:VNRX) by 16.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 629,639 shares of the company’s stock after purchasing an additional 87,195 shares during the quarter. Vanguard Group Inc. owned 0.80% of VolitionRx worth $451,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.